Overview


According to FutureWise analysis the market for gout therapeutics is expected to register a CAGR of 15.72% from 2023-2031.

The development of gouty arthritis results from the metabolic illness known as gout, which is brought on by an increase in the body's uric acid levels. The big toe is typically affected, but other joints may also experience sudden, acute bouts of pain, swelling, redness, and tenderness. In general, men experience it earlier than women. For women, it typically happens after menopause. Because they have had higher levels of uric acid for the majority of their lives, men maybe three times more likely to develop it than women. Although there are gout treatments, therapy should be personalized for each patient. Treatment options rely on various criteria, including renal function, other health conditions, personal preferences, and others. Patients may require medicine to lessen their high blood uric acid levels, which increases their risk of developing gout. Urate crystal deposits in and around the joints may develop over time due to elevated uric acid levels in the blood. White blood cells may be drawn to these crystals, resulting in excruciatingly painful gout attacks and persistent arthritis.

Everyone is susceptible to the prevalent and painful form of arthritis known as gout. Both pharmaceutical and non-pharmacological treatments are required for gout. Different stages of clinical development are being applied to newer medications that target various inflammatory mediators, enzymes, or transporters. There is moderate to strong evidence that several medications are beneficial for treating pain in people with acute gout. When beginning urate-lowering therapy (ULT), NSAIDs, colchicine, and glucocorticoids have long been used as prophylaxis and to treat the inflammation brought on by acute gout attacks. Each is regarded as a first-line treatment for acute gout, and combined therapy may be utilized in extreme situations. More individuals are experiencing gout, which is dangerous for their health. Even though gout treatment has been around for a while, managing the condition still presents many difficulties. The gout therapeutics market is expected to grow over the forecast period due to key players increased investment in R&D initiatives.

FutureWise Market Research has published a report that provides an insightful analysis of gout therapeutics market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts, the gout therapeutics market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Teijin Pharma Limited,
  • Horizon Pharma plc,
  • Novartis AG,
  • Merck & Co. Inc.,
  • Ironwood Pharmaceuticals, Inc.,
  • Grunenthal Group,
  • JW Pharmaceutical,
  • Takeda Pharmaceutical Company Limited,
  • Selecta Biosciences, Inc.,
  • AstraZeneca,
  • Regeneron Pharmaceuticals, Inc.

Recent developments by key players in Gout Therapeutics Market:

In March 2022- The successful outcomes of a Phase 2a clinical trial using ABP-671 to treat severe gout were announced by Atom Bioscience.

Gout, the type of inflammatory arthritis, is characterized by recurrent, excruciatingly painful acute bouts. Over the past few decades, its prevalence and incidence have increased. Hyperuricemia, genetics, dietary factors, alcohol use, metabolic syndrome, hypertension, obesity, use of diuretics, and chronic renal disease can cause gout. Numerous studies have shown that the primary care approach to treating gout is ineffective, which may contribute to the rise in the prevalence of clinically severe symptomatic gout. Obesity, diabetes, and hypertension are common among gout patients in the UK and Germany, according to research. Gout is expected to become more prevalent as the population ages, raising risk factors. Moreover, in addition to hyperuricemia, gout is caused by urate crystal deposition in and around the joints. Anti-hyperuricemia drugs are also referred to as antigout medications. Anti-hyperuricemia medications lower blood uric acid levels by either hastening uric acid excretion through the urine or preventing extra uric acid yield. Therefore, increased demand for urate-lowering medications is anticipated to increase sales of drugs that treat hyperuricemia. The market is also growing as a result of higher commercial activities, clinical drug development studies for treating excess uric acid, and awareness-raising campaigns for gout and its effects. However, it is expected that the market's growth will be constrained over the forecast period by middle- and low-income countries' lack of awareness of gout therapies and their advantages over conventional treatments. Strict regulations and the patent expiration of some well-known drugs further hinder the global gout therapeutics market.

By Disease Condition

  • Acute Gout
  • Chronic Gout

By Drug Class

  • Colchicine
  • Antihyperuricemic agents (Urate-Lowering Drugs)
  • Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • Corticosteroids
  • Biologic Response Modifiers (Biologics)

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

By Region

  • Europe
  • North America
  • Asia Pacific
  • Latin America
  • Middle East & Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. With a high market attractiveness index, the area is anticipated to have an extremely lucrative market during the forecast period. The U.S.'s expanding comorbidity burden and rising incidence of gout are projected to drive the market in the region. The most prevalent inflammatory arthritis in the region is gout. The prevalence has risen during the past few decades, according to numerous research. In the past 20 years, oral urate-lowering medicines have been used to treat approximately a third of the more than nine million patients. In the last several years, a significant increase in the number of patients with gout-related disabilities has been seen, which is anticipated to boost market growth in the region.

  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • Emerging players which are growing rapidly

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth

  • To provide with an exhaustive analysis on the Gout Therapeutics Market by disease condition, by drug class, by distribution channel, and by region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches.

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Gout Therapeutic Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Gout Therapeutic Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Gout Therapeutic Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Gout Therapeutic Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Gout Therapeutic Market, By Disease Condition Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Acute Gout
        2. Chronic Gout

  • 8.   Global Gout Therapeutic Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Colchicine
        2. Antihyperuricemic agents (Urate-Lowering Drugs)
        3. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
        4. Corticosteroids
        5. Biologic Response Modifiers (Biologics)

  • 9.   Global Gout Therapeutic Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospital Pharmacy
        2. Retail Pharmacy
        3. Online Pharmacy

  • 10.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Taiwan
         2.9. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)
    •   1. Teijin Pharma Limited
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Horizon Pharma plc
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Novartis AG
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. MerckCo. Inc.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        15.5 . Ironwood Pharmaceuticals, Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        15.6 . Grunenthal Group
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. JW Pharmaceutical
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Takeda Pharmaceutical Company Limited
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Selecta Biosciences, Inc.
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. AstraZeneca
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. Regeneron Pharmaceuticals, Inc
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview

  • 16.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 17.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients